Expression of hypoxia-inducible 2 (HIG2) protein in uterine cancer

For both cervical cancer (UCC) and endometrial cancer (EMC) there are no effective prognostic markers. In this study, we evaluated HIG2 protein expression in 332 uterine cancers (186 UCCs and 146 EMCs) and examined the relationship between HIG2 protein expression and clinical factors, including prognosis. Totally, HIG2 expression was detected in 58% of UCC and 66% of EMC. However, there was no significant relationship between HIG2 expression and age, clinical stage and histology in either UCC or EMC. In addition, HIG2 protein expression was not related to prognosis of UCC or EMC. The positivity rate of HIG2 protein was 56% and 61% in early-stage UCC and EMC, respectively and 67% in non-squamous cell carcinoma of UCC. The positivity rate of HIG2 protein was high even in early-stage UCC and EMC

Endometrial cancer; Cervical cancer; Adenocarcinoma; HIG2

[1] Ioka A., Tsukuma H., Ajiki W., Oshima A.: “Trends in uterine cancer incidence in Japan 1975-98”. Jpn. J. Clin. Oncol., 2003, 33, 645.

[2] Tsuda H., Ito Y.M., Ohashi Y., Wong K.K., Hashiguchi Y., Welch W.R. et al.: “Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses”. Clin. Cancer Res., 2005, 11 (19 Pt 1), 6880.

[3] Nishimura S., Tsuda H., Ito K., Takano M., Terai Y., Jobo T. et al.: “Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas”. Int. J. Gynecol. Cancer, 20, 220.

[4] Togashi A., Katagiri T., Ashida S., Fujioka T., Maruyama O., Wakumoto Y. et al.: “Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy”. Cancer Res., 2005, 65, 4817.

[5] Lozza L., Merola M., Fontanelli R., Stefanon B., Seregni E., Bombardieri E. et al.: “Cancer of the uterine cervix: clinical value of squamous cell carcinoma antigen (SCC) measurements”. Anticancer Res., 1997, 17 (1B), 525.

[6] Ngan H.Y., Cheung A.N., Lauder I.J., Wong L.C., Ma H.K.: “Prognostic significance of serum tumour markers in carcinoma ofthe cervix”. Eur. J. Gynaecol. Oncol., 1996, 17, 512.

[7] Massuger L.F., Koper N.P., Thomas C.M., Dom K.E., Schijf C.P.: “Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations”. Gynecol. Oncol., 1997, 64, 473.

[8] Ihara Y., Shimizu T., Kawaguchi K., Yomura W., Fujiwara T., Inoue K.: “Serum CA125 and CA19-9 levels in adenocarcinoma of the uterine cervix and endometrial carcinoma”. Nippon Sanka Fujinka Gakkai Zasshi, 1988, 40, 1711.

[9] Duk J.M., Aalders J.G., Fleuren G.J., de Bruijn H.W.: “CA 125: a useful marker in endometrial carcinoma”. Am. J. Obstet. Gynecol., 1986, 155, 1097.

[10] Panici P.B., Scambia G., Baiocchi G., Perrone L., Greggi S., Battaglia F. et al.: “Multiple serum markers in patients with endometrial cancer”. Gynecol. Obstet. Invest., 1989, 27, 208.

[11] Soper J.T., Berchuck A., Olt G.J., Soisson A.P., Clarke-Pearson

D. L., Bast R.C. Jr.: “Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma”. Am. J. Obstet. Gynecol., 1990, 163 (4 Pt 1), 1204.

[12] Speers W.C., Picaso L.G., Silverberg S.G.: “Immunohistochemical localization of carcinoembryonic antigen in microglandular hyperplasia and adenocarcinoma of the endocervix”. Am. J. Clin. Pathol., 1983, 79, 105.

[13] Neunteufel W., Bieglmayer C., Breitenecker G.: “CA19-9, CA125 and CEA in endometrial carcinoma tissue and its relation to hormone receptor content and histological grading”.Arch. Gynecol. Obstet., 1988, 244, 47.

[14] Podczaski E., Kaminski P.F., Zaino R.: “CA125 and CA 19-9 immunolocalization in normal, hyperplastic, and carcinomatous endometrium”. Cancer, 1993, 71, 2551.

[15] Yamazawa K., Hirashiki K., Usui H., Mitsuhashi A., Matsui H., Sekiya S.: “Discordance between serum level and tissue immunohistochemical staining of CA125 in endometrioid adenocarcinoma of the uterine corpus”. Int. J. Gynecol. Pathol., 2005, 24, 254.

[16] Berchuck A., Soisson A.P., Clarke-Pearson D.L., Soper J.T., Boyer C. M., Kinney R.B. et al.: “Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential”. Cancer Res., 1989, 49, 2091.